A PHASE IIIB, SINGLE-ARM, MULTICENTER STUDY TO ACCESS EFFICACY, SAFETY, AND TOLERABILITY OF ROPEGINTERFERON ALFA-2B-NJFT (P1101) IN ADULT PATIENTS WITH POLYCYTHEMIA VERA (PV)

Registry ID

A22-203

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PHARMAESSENTIA CORPORATION

Start date

2024-10-30

Last update

2023-02-02

Conditions

• POLYCYTHEMIA VERA (PV)

Related clinical trials

• AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424) STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT (LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT
• A PHASE 3 STUDY OF THE HEPCIDIN MIMETIC RUSFERTIDE (PTG-300) IN PATIENTS WITH POLYCYTHEMIA VERA
• A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MOMELOTINIB IN SUBJECTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA

View on source registry